iPSCs: On the Road to Reprogramming Aging

Trends in Molecular Medicine

Volumn 22, Issue 8, 2016, Pages 713-724

  Soria Valles, Clara ^a   López Otín, Carlos ^a  

^a DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

Author keywords

Alzheimer's disease; iPSCs; Parkinson's disease; progeria

Indexed keywords

AGING; ALZHEIMER DISEASE; ANIMAL CELL; CELL NUCLEUS MEMBRANE; DNA DAMAGE; DNA REPAIR; HUMAN; HUMAN CELL; INDUCED PLURIPOTENT STEM CELL; NONHUMAN; NUCLEAR REPROGRAMMING; PARKINSON DISEASE; PROGERIA; REJUVENATION; REVIEW; SOMATIC CELL; ANIMAL; CYTOLOGY; METABOLISM; PATHOLOGY;

AGING; ALZHEIMER DISEASE; ANIMALS; CELLULAR REPROGRAMMING; HUMANS; INDUCED PLURIPOTENT STEM CELLS; PARKINSON DISEASE;

EID: 84973582082     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2016.05.010     Document Type: Review

References (97)

1. 1 Takahashi, K., Yamanaka, S., Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126 (2006), 663–676.
2. 2 Takahashi, K., Yamanaka, S., A decade of transcription factor-mediated reprogramming to pluripotency. Nat. Rev. Mol. Cell. Biol. 17 (2016), 183–193.
3. 3 Phanthong, P., et al. Is aging a barrier to reprogramming? Lessons from induced pluripotent stem cells. Biogerontology 14 (2013), 591–602.
4. 4 Mahmoudi, S., Brunet, A., Aging and reprogramming: a two-way street. Curr. Opin. Cell Biol. 24 (2012), 744–756.
5. 5 Somers, A., et al. Generation of transgene-free lung disease-specific human induced pluripotent stem cells using a single excisable lentiviral stem cell cassette. Stem Cells 28 (2010), 1728–1740.
6. 6 Lopez-Otin, C., et al. The hallmarks of aging. Cell 153 (2013), 1194–1217.
7. 7 Lapasset, L., et al. Rejuvenating senescent and centenarian human cells by reprogramming through the pluripotent state. Genes Dev. 25 (2011), 2248–2253.
8. 8 Soria-Valles, C., et al. NF-κB activation impairs somatic cell reprogramming in ageing. Nat. Cell. Biol. 17 (2015), 1004–1013.
9. 9 Rohani, L., et al. The aging signature: a hallmark of induced pluripotent stem cells?. Aging Cell 13 (2014), 2–7.
10. 10 Gordon, L.B., et al. Progeria: a paradigm for translational medicine. Cell 156 (2014), 400–407.
11. 11 Varela, I., et al. Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat. Med. 14 (2008), 767–772.
12. 12 Osorio, F.G., et al. Splicing-directed therapy in a new mouse model of human accelerated aging. Sci. Transl. Med., 3, 2011, 106ra107.
13. 13 Svendsen, C.N., Back to the future: how human induced pluripotent stem cells will transform regenerative medicine. Hum. Mol. Genet. 22 (2013), R32–R38.
14. 14 Freije, J.M., Lopez-Otin, C., Reprogramming aging and progeria. Curr. Opin. Cell Biol. 24 (2012), 757–764.
15. 15 Miller, J.D., et al. Human iPSC-based modeling of late-onset disease via progerin-induced aging. Cell Stem Cell 13 (2013), 691–705.
16. 16 Vera, E., Studer, L., When rejuvenation is a problem: challenges of modeling late-onset neurodegenerative disease. Development 142 (2015), 3085–3089.
17. 17 Rosengardten, Y., et al. Stem cell depletion in Hutchinson–Gilford progeria syndrome. Aging Cell 10 (2011), 1011–1020.
18. 18 Mertens, J., et al. Directly reprogrammed human neurons retain aging-associated transcriptomic signatures and reveal age-related nucleocytoplasmic defects. Cell Stem Cell 17 (2015), 705–718.
19. 19 Fanjul-Fernandez, M., et al. Matrix metalloproteinase Mmp-1a is dispensable for normal growth and fertility in mice and promotes lung cancer progression by modulating inflammatory responses. J. Biol. Chem. 288 (2013), 14647–14656.
20. 20 Cheung, H.H., et al. Telomerase protects Werner syndrome lineage-specific stem cells from premature aging. Stem Cell Rep. 2 (2014), 534–546.
21. 21 Shimamoto, A., et al. Reprogramming suppresses premature senescence phenotypes of Werner syndrome cells and maintains chromosomal stability over long-term culture. PLoS One, 9, 2014, e112900.
22. 22 Kraemer, K.H., et al. Xeroderma pigmentosum, trichothiodystrophy and Cockayne syndrome: a complex genotype–phenotype relationship. Neuroscience 145 (2007), 1388–1396.
23. 23 Marteijn, J.A., et al. Understanding nucleotide excision repair and its roles in cancer and ageing. Nat. Rev. Mol. Cell. Biol. 15 (2014), 465–481.
24. 24 Andrade, L.N., et al. Evidence for premature aging due to oxidative stress in iPSCs from Cockayne syndrome. Hum. Mol. Genet. 21 (2012), 3825–3834.
25. 25 Vessoni, A.T., et al. Cockayne syndrome-derived neurons display reduced synapse density and altered neural network synchrony. Hum. Mol. Genet. 25 (2016), 1271–1280.
26. 26 Dupuy, A., Sarasin, A., DNA damage and gene therapy of xeroderma pigmentosum, a human DNA repair-deficient disease. Mutat. Res. 776 (2015), 2–8.
27. 27 Fu, L., et al. Modeling xeroderma pigmentosum associated neurological pathologies with patients-derived iPSCs. Protein Cell 7 (2016), 210–221.
28. 28 Nayler, S., et al. Induced pluripotent stem cells from ataxia-telangiectasia recapitulate the cellular phenotype. Stem Cells Transl. Med. 1 (2012), 523–535.
29. 29 Fukawatase, Y., et al. Ataxia telangiectasia derived iPS cells show preserved x-ray sensitivity and decreased chromosomal instability. Sci. Rep., 4, 2014, 5421.
30. 30 Lee, P., et al. SMRT compounds abrogate cellular phenotypes of ataxia telangiectasia in neural derivatives of patient-specific hiPSCs. Nat. Commun., 4, 2013, 1824.
31. 31 Kee, Y., D'Andrea, A.D., Molecular pathogenesis and clinical management of Fanconi anemia. J. Clin. Invest. 122 (2012), 3799–3806.
32. 32 Raya, A., et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 460 (2009), 53–59.
33. 33 Muller, L.U., et al. Overcoming reprogramming resistance of Fanconi anemia cells. Blood 119 (2012), 5449–5457.
34. 34 Yung, S.K., et al. Brief report: human pluripotent stem cell models of fanconi anemia deficiency reveal an important role for fanconi anemia proteins in cellular reprogramming and survival of hematopoietic progenitors. Stem Cells 31 (2013), 1022–1029.
35. 35 Suzuki, N.M., et al. Pluripotent cell models of fanconi anemia identify the early pathological defect in human hemoangiogenic progenitors. Stem Cells Transl. Med. 4 (2015), 333–338.
36. 36 Agarwal, S., et al. Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients. Nature 464 (2010), 292–296.
37. 37 Batista, L.F., et al. Telomere shortening and loss of self-renewal in dyskeratosis congenita induced pluripotent stem cells. Nature 474 (2011), 399–402.
38. 38 Gruenbaum, Y., Medalia, O., Lamins: the structure and protein complexes. Curr. Opin. Cell Biol. 32 (2015), 7–12.
39. 39 Cau, P., et al. Nuclear matrix, nuclear envelope and premature aging syndromes in a translational research perspective. Semin. Cell Dev. Biol. 29 (2014), 125–147.
40. 40 Eriksson, M., et al. Recurrent de novo point mutations in lamin A cause Hutchinson–Gilford progeria syndrome. Nature 423 (2003), 293–298.
41. 41 De Sandre-Giovannoli, A., et al. Lamin a truncation in Hutchinson–Gilford progeria. Science, 300, 2003, 2055.
42. 42 Nissan, X., et al. Unique preservation of neural cells in Hutchinson–Gilford progeria syndrome is due to the expression of the neural-specific miR-9 microRNA. Cell Rep. 2 (2012), 1–9.
43. 43 Liu, G.H., et al. Recapitulation of premature ageing with iPSCs from Hutchinson–Gilford progeria syndrome. Nature 472 (2011), 221–225.
44. 44 Zhang, J., et al. A human iPSC model of Hutchinson Gilford progeria reveals vascular smooth muscle and mesenchymal stem cell defects. Cell Stem Cell 8 (2011), 31–45.
45. 45 Ho, J.C., et al. Generation of induced pluripotent stem cell lines from 3 distinct laminopathies bearing heterogeneous mutations in lamin A/C. Aging (Albany NY) 3 (2011), 380–390.
46. 46 Xiong, Z.M., et al. An inhibitory role of progerin in the gene induction network of adipocyte differentiation from iPS cells. Aging (Albany NY) 5 (2013), 288–303.
47. 47 Puente, X.S., et al. Exome sequencing and functional analysis identifies BANF1 mutation as the cause of a hereditary progeroid syndrome. Am. J. Hum. Genet. 88 (2011), 650–656.
48. 48 Cabanillas, R., et al. Nestor–Guillermo progeria syndrome: a novel premature aging condition with early onset and chronic development caused by BANF1 mutations. Am. J. Med. Genet. A 155A (2011), 2617–2625.
49. 49 Jovicic, A., et al. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat. Neurosci. 18 (2015), 1226–1229.
50. 50 Freibaum, B.D., et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature 525 (2015), 129–133.
51. 51 Park, I.H., et al. Disease-specific induced pluripotent stem cells. Cell 134 (2008), 877–886.
52. 52 Soldner, F., et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136 (2009), 964–977.
53. 53 Nguyen, H.N., et al. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell 8 (2011), 267–280.
54. 54 Sanchez-Danes, A., et al. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol. Med. 4 (2012), 380–395.
55. 55 Sanders, L.H., et al. LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction. Neurobiol. Dis. 62 (2014), 381–386.
56. 56 Liu, G.H., et al. Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. Nature 491 (2012), 603–607.
57. 57 Oliveira, L.M., et al. Elevated alpha-synuclein caused by SNCA gene triplication impairs neuronal differentiation and maturation in Parkinson's patient-derived induced pluripotent stem cells. Cell Death Dis., 6, 2015, e1994.
58. 58 Chung, C.Y., et al. Identification and rescue of alpha-synuclein toxicity in Parkinson patient-derived neurons. Science 342 (2013), 983–987.
59. 59 Seibler, P., et al. Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells. J. Neurosci. 31 (2011), 5970–5976.
60. 60 Imaizumi, Y., et al. Mitochondrial dysfunction associated with increased oxidative stress and alpha-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Mol. Brain, 5, 2012, 35.
61. 61 Ren, Y., et al. Parkin mutations reduce the complexity of neuronal processes in iPSC-derived human neurons. Stem Cells 33 (2015), 68–78.
62. 62 Jiang, H., et al. Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells. Nat. Commun., 3, 2012, 668.
63. 63 Soldner, F., et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 146 (2011), 318–331.
64. 64 Sundberg, M., et al. Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. Stem Cells 31 (2013), 1548–1562.
65. 65 Hallett, P.J., et al. Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease. Cell Stem Cell 16 (2015), 269–274.
66. 66 Caiazzo, M., et al. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature 476 (2011), 224–227.
67. 67 Cai, J., et al. Dopaminergic neurons derived from human induced pluripotent stem cells survive and integrate into 6-OHDA-lesioned rats. Stem Cell Dev. 19 (2010), 1017–1023.
68. 68 Krstic, D., Knuesel, I., Deciphering the mechanism underlying late-onset Alzheimer disease. Nat. Rev. Neurol. 9 (2013), 25–34.
69. 69 Mungenast, A.E., et al. Modeling Alzheimer's disease with human induced pluripotent stem (iPS) cells. Mol. Cell. Neurosci. 73 (2016), 13–31.
70. 70 Young, J.E., et al. Elucidating molecular phenotypes caused by the SORL1 Alzheimer's disease genetic risk factor using human induced pluripotent stem cells. Cell Stem Cell 16 (2015), 373–385.
71. 71 Israel, M.A., et al. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 482 (2012), 216–220.
72. 72 Kondo, T., et al. Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness. Cell Stem Cell 12 (2013), 487–496.
73. 73 Muratore, C.R., et al. The familial Alzheimer's disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons. Hum. Mol. Genet. 23 (2014), 3523–3536.
74. 74 Lee, J.K., et al. Acid sphingomyelinase modulates the autophagic process by controlling lysosomal biogenesis in Alzheimer's disease. J. Exp. Med. 211 (2014), 1551–1570.
75. 75 Mahairaki, V., et al. Induced pluripotent stem cells from familial Alzheimer's disease patients differentiate into mature neurons with amyloidogenic properties. Stem Cells Dev. 23 (2014), 2996–3010.
76. 76 Yagi, T., et al. Modeling familial Alzheimer's disease with induced pluripotent stem cells. Hum. Mol. Genet. 20 (2011), 4530–4539.
77. 77 Banito, A., et al. Senescence impairs successful reprogramming to pluripotent stem cells. Genes Dev. 23 (2009), 2134–2139.
78. 78 Suhr, S.T., et al. Mitochondrial rejuvenation after induced pluripotency. PLoS One, 5, 2010, e14095.
79. 79 Kawamura, T., et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 460 (2009), 1140–1144.
80. 80 Marion, R.M., et al. Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells. Cell Stem Cell 4 (2009), 141–154.
81. 81 Hong, H., et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 460 (2009), 1132–1135.
82. 82 Marion, R.M., et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 460 (2009), 1149–1153.
83. 83 Wang, T., et al. The histone demethylases Jhdm1a/1b enhance somatic cell reprogramming in a vitamin-C-dependent manner. Cell Stem Cell 9 (2011), 575–587.
84. 84 Chen, X., et al. Valproic acid enhances iPSC induction from human bone marrow-derived cells through the suppression of reprogramming-induced senescence. J. Cell. Physiol. 231 (2016), 1719–1727.
85. 85 Hannum, G., et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol. Cell 49 (2013), 359–367.
86. 86 Onder, T.T., et al. Chromatin-modifying enzymes as modulators of reprogramming. Nature 483 (2012), 598–602.
87. 87 Frobel, J., et al. Epigenetic rejuvenation of mesenchymal stromal cells derived from induced pluripotent stem cells. Stem Cell Rep. 3 (2014), 414–422.
88. 88 Zhang, W., et al. Aging stem cells. A Werner syndrome stem cell model unveils heterochromatin alterations as a driver of human aging. Science 348 (2015), 1160–1163.
89. 89 Zhang, J., et al. Metabolic regulation in pluripotent stem cells during reprogramming and self-renewal. Cell Stem Cell 11 (2012), 589–595.
90. 90 Chen, T., et al. Rapamycin and other longevity-promoting compounds enhance the generation of mouse induced pluripotent stem cells. Aging Cell 10 (2011), 908–911.
91. 91 Sharma, A., et al. The role of SIRT6 protein in aging and reprogramming of human induced pluripotent stem cells. J. Biol. Chem. 288 (2013), 18439–18447.
92. 92 Ma, T., et al. Atg5-independent autophagy regulates mitochondrial clearance and is essential for iPSC reprogramming. Nat. Cell. Biol. 17 (2015), 1379–1387.
93. 93 Osorio, F.G., et al. Nuclear lamina defects cause ATM-dependent NF-kappaB activation and link accelerated aging to a systemic inflammatory response. Genes Dev. 26 (2012), 2311–2324.
94. 94 Ohnishi, K., et al. Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation. Cell 156 (2014), 663–677.
95. 95 Abad, M., et al. Reprogramming in vivo produces teratomas and iPS cells with totipotency features. Nature 502 (2013), 340–345.
96. 96 Rakovic, A., et al. Phosphatase and tensin homolog (PTEN)-induced putative kinase 1 (PINK1)-dependent ubiquitination of endogenous Parkin attenuates mitophagy: study in human primary fibroblasts and induced pluripotent stem cell-derived neurons. J. Biol. Chem. 288 (2013), 2223–2237.
97. 97 Shaltouki, A., et al. Mitochondrial alterations by PARKIN in dopaminergic neurons using PARK2 patient-specific and PARK2 knockout isogenic iPSC lines. Stem Cell Rep. 4 (2015), 847–859.